Acta Dermatovenerol Alp Pannonica Adriat
March 2023
Linear IgA bullous dermatosis (LABD) is a rare autoimmune bullous disease characterized by linear IgA deposition along the skin basal membrane. In children, LABD classically presents with a "cluster of jewels" appearance, whereas in adults the classic presentation is itchy papules with tense vesicles and bullae on an erythematous base. We report the case of a 41-year-old woman with LABD that we suspect was induced by acute myeloid leukemia presenting with multiple vesicles and bullae that coalesced, forming the typical clinical manifestation of LABD and confirmed with histopathological and direct immunofluorescence.
View Article and Find Full Text PDFActa Dermatovenerol Alp Pannonica Adriat
March 2023
Syringomas are eccrine-derived benign adnexal neoplasms with the highest prevalence in early adulthood. They predominantly occur in females. They are commonly located on the face, particularly the lower eyelids, which have a high demand for cosmetic enhancement.
View Article and Find Full Text PDFBackground: Hydroquinone, which is considered the gold standard skin depigmenting agent, has been associated with multiple side effects. Lately, deoxyarbutin has been suggested to be an alternative of hydroquinone with better safety profile.
Objective: To compare the depigmenting effect of 2% deoxyarbutin and 4% hydroquinone sera.
Tattoos have long become a part of human civilization. However, as the number of people who get tattoos increases, so is the number of people who wish to have their tattoos removed. Compared to other methods, laser-based devices are associated with the best efficacy and least side effects in tattoo removal.
View Article and Find Full Text PDFJ Clin Aesthet Dermatol
July 2020
We investigated the efficacy and tolerability of nicotinamide cream plus an antibacterial adhesive agent and zinc-pyrrolidone carboxylic acid compared to placebo in patients with moderate acne vulgaris (MAV) in Indonesia. This was a multicenter, double-blind, randomized, placebo-controlled, parallel-group study conducted in five teaching hospitals in Indonesia from August 2016 to January 2017. Eligible participants included 140 patients with MAV, aged 12 to 50 years, who were enrolled and randomly divided into two groups to receive either adapalene and the study formulation or adapalene and a placebo cream twice daily for six weeks.
View Article and Find Full Text PDF